Delving into the Latest Updates on JND-3229 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

EGFR C797S

Mechanism

EGFR C797S inhibitors(Epidermal Growth Factor Receptor C797S inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Neoplasms

Inactive Indication-

Originator Organization

Jinan University

Active Organization

Jinan University

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

EGFR^C797S mutation inducing resistance against third generation EGFR inhibitor drugs is an emerging "unmet clinical need" for nonsmall cell lung cancer patients. The pyrimidopyrimidinone derivative JND3229 was identified as a new highly potent EGFR^C797S inhibitor with single digit nM potency. It also exhibited good in vitro and in vivo monodrug anticancer efficacy in a xenograft mouse model of BaF3/EGFR^{19D/T790M/C797S} cells. A high-resolution X-ray crystallographic structure was also determined to elucidate the interactions between JND3229 and EGFR^T790M/C797S. Our study provides an important structural and chemical basis for future development of new generation EGFR^C797S inhibitors as anticancer drugs.

100 Deals associated with JND-3229

Login to view more data